Prevalence of Liver Fibrosis and Progression of Liver Fibrosis

N/AUnknownNCT01208376

Helen Kovari-Kramer195 enrolled

Overview

Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection. Study aim is first to evaluate the prevalence of liver fibrosis and cirrhosis in HIV-infected patients with chronic ALT elevation and no chronic viral hepatitis using non-invasive diagnostic tests and second to find associated factors with significant fibrosis and cirrhosis. In a second longitudinal part we intend to assess fibrosis progression within 1 and 3 years.

Study Type

OBSERVATIONAL

Enrollment

195

Conditions

HIV Infection and Chronic Alanine Aminotransferase Elevation

Interventions

FibroscanOTHER

Fibroscan and Serum Fibrose-marker

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: Case patients: * HIV-1 infection * no hepatitis B and C coinfection * chronic alanine aminotransferase (ALT) elevation after 1.1.2007 * signed informed consent * no other common cause of liver disease Control patients: * HIV-infection * no hepatitis B and C coinfection * no ALT elevation after 1.1.2002, the date when ALT values were regularly collected in the Swiss HIV Cohort Study (SHCS) * no known chronic liver disease Exclusion criteria: please see inclusion criteria

Locations (1)

University Hospital Zurich

Zurich, Switzerland

Outcomes

Primary Outcomes

Liverfibrosis

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.